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and speciﬁcity) using ANCOVA, and construct validity using
exploratory factor analysis with varimax rotation. RESULTS:
Eighty-ﬁve students (2A = 47; 2B = 38) completed the study.
Baseline HRQL was not statistically different. The reliability
coefﬁcient for the instrument was higher than 80%. ANCOVA
showed reasonable responsiveness, i.e., statistically signiﬁcant
differences between Scenario 1–2A and no differences between
Scenario 1–2B, as expected. Factor analysis indicated 7 factors;
some modiﬁcation would be needed in two of the items. 
CONCLUSION: Initial validation of an HRQL instrument for
multiple chronic conditions indicated good reliability and
responsiveness; however minor modiﬁcations would be needed
to improve construct validity before the instrument is ready for
use in a MTM clinic.
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OBJECTIVES: The Kansas City Cardiomyopathy Questionnaire
(KCCQ) is a valid, reliable and sensitive measure through which
to quantify heart failure (HF) patients’ health status (symptoms,
function and quality of life). Prior to its use in an international
clinical trial of HF patients, the original 23-item KCCQ needed
to be translated into 30 languages/cultures. METHODS: The
original instrument was developed in US English, with input
from Mapi Research Institute on the best terminology to facili-
tate future translations. To ensure conceptual equivalence and
cultural relevance, the translation process was conducted by spe-
cialists in each target country across the EU, CEE, and Latin
America, using the following standardized methodology: 1) two
independent forward translations by professional translators
who were native speakers of the target language and ﬂuent in
English; 2) comparison and reconciliation of the translations by
the specialist in the target country and the translators; 3) back-
ward translation by a native English speaker; 4) comparison of
source and backward version with the original KCCQ developer;
5) review by a clinician; 6) comprehension test on 5 HF patients;
and 7) international harmonization. RESULTS: The translation
process revealed challenges where the formulation of the origi-
nal items made use of speciﬁc examples to describe an item
concept. Since a literal translation of these speciﬁc examples was
not always culturally relevant, these speciﬁc examples were
replaced by generic terms. After completing these changes and
international harmonization, all 30 versions were certiﬁed by
Mapi to be conceptually equivalent to the original questionnaire
and culturally relevant for each country. CONCLUSION: The
KCCQ, translated into 30 languages, can be used as a valid and
reliable instrument to evaluate HF patients’ health status glob-
ally. Harmonization of these versions will facilitate international
comparison of results and pooling of data when used in inter-
national studies involving quantiﬁcation of HF patients’ health
status.
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OBJECTIVES: To document the recent dynamic changes in
prevalence of obesity and medical comorbidities and costs for
the U.S. general population. METHODS: This study analyzed
data from the 2000 and 2004 Medical Expenditure Panel Survey
(MEPS), a nationally representative panel data. Based on Body
Mass Index (BMI), weight groups were deﬁned as Underweight
(UW, BMI < 18.5), Normal Weight (NW, BMI 18.5–24.9), Over-
weight (OW, BMI 25–29.9), Obese I (BMI 30–34.9), Obese II
(BMI 35–39.9), and Obese III (BMI <= 40). Univariate analyses
were conducted to examine changes in obesity prevalence, as
well as the trend differentials in demographic and socioeconomic
status. Trends in co-morbidities and medical costs were com-
pared among different weight groups across years. All estimates
are weighted to be nationally representative. RESULTS: The
prevalence of obesity increased from 22.5% to 25.9% between
year 2000 and 2004 (Obese I: 14.6% vs 16.4%, Obese II: 5.1%
vs 6.1%, and Obese III: 2.8% vs 3.4%). Obesity increased more
among African-Americans, individuals who had higher educa-
tion, higher income, and public health insurance. For both years,
obesity was consistently associated with the greatest risk of dia-
betes, high blood pressure, cardiovascular disease, asthma and
joint pain (p > 0.001). In 2000 dollars, the change in total
medical costs was from $3159 in 2000 to $3854 in 2004 for
obese groups; $2324 to $3000 for NW; and $2345 to $3088 
for OW, all at highly signiﬁcant level of p < 0.001. Obesity
related physician ofﬁce-based costs, ER costs and RX costs were
also increased as compared to other groups (p < 0.001). CON-
CLUSION: The prevalence of obesity has increased since 2000,
resulting in an increase in obesity related comorbidities and
medical costs. This study also showed that obesity may be asso-
ciated with race, socioeconomic status, education, and health
insurance.
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OBJECTIVES: The incretin mimetic exenatide improves gly-
caemic control with associated weight reduction in patients with
type 2 diabetes (T2DM) treated with metformin (MET), a
sulphonylurea (SU), or both. As pharmacokinetics and pharma-
codynamics for a given drug can vary with age, we explored exe-
natide’s efﬁcacy and safety for different age groups. METHODS:
Patients who completed 2 y of exenatide treatment in this interim
analysis (N = 283, 63% male, age 57.3 ± 9.7 y; weight 100 ±
19 kg, HbA1c 8.3 ± 1.0%, fasting plasma glucose [FPG] 9.7 ±
2.5 mmol/L, duration of diabetes 8.1 ± 6.1 y, mean ± SD) had
statistically signiﬁcant (P < 0.05) mean (±SE) reductions in HbA1c
(−1.1 ± 0.1%), FPG (−1.4 ± 0.2 mmol/L), and weight (−4.7 ±
0.3 kg). RESULTS: When examined by baseline age (<45 y, n =
26, 45–54 y, n = 91, 55–64 y, n = 97, ≥65 y, n = 69), mean (±SE)
reductions in HbA1c> (−1.1 ± 0.2%, −1.0 ± 0.1%, −1.3 ± 0.1%,
and −1.2 ± 0.1%, respectively), weight (−3.6 ± 1.0 kg, −4.6 ±
0.7 kg, −4.9 ± 0.6 kg, and −4.9 ± 0.6 kg), and FPG (−1.1 ±
0.4 mmol/L, −1.1 ± 0.3 mmol/L, −1.7 ± 0.3 mmol/L, and −1.5 
± 0.3 mmol/L) were not age dependent. Overall, 54% (N = 283)
of eligible patients completed 2 y of exenatide, with withdrawal
of consent (15%) and adverse event (9%) the most common
reasons for withdrawal. Completion rates varied by age group
(35%, 51%, 58%, and 68%), as did the frequency of those with-
drawing due to adverse events (4%, 7%, 11%, and 11%) and
withdrawal of consent (19%, 18%, 15%, and 8%). Nausea was
the most common adverse event for all age groups. Incidence of
